Gilead Sciences, Inc. $GILD Shares Sold by Financial Advisors Network Inc.

Key Points

• Financial Advisors Network Inc. reduced its stake in Gilead Sciences by 1.5%, owning 156,016 shares worth approximately $17.48 million, making it the firm's 9th largest investment.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, with an annualized dividend yield of 2.7% and a payout ratio of 62.95%.
• The company reported a net margin of 21.86% and a return on equity of 50.99%, with quarterly revenue of $7.08 billion, exceeding analyst expectations.

Financial Advisors Network Inc. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 156,016 shares of the biopharmaceutical company's stock after selling 2,309 shares during the quarter. Gilead Sciences makes up about 2.9% of Financial Advisors Network Inc.'s holdings, making the stock its 9th biggest position. Financial Advisors Network Inc.'s holdings in Gilead Sciences were worth $17,482,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Gabelli Funds LLC acquired a new stake in Gilead Sciences in the 4th quarter worth $387,000. Commerce Bank increased its holdings in shares of Gilead Sciences by 1.0% during the 4th quarter. Commerce Bank now owns 73,195 shares of the biopharmaceutical company's stock worth $6,761,000 after purchasing an additional 701 shares during the period. Ossiam increased its holdings in shares of Gilead Sciences by 3.2% during the 4th quarter. Ossiam now owns 31,975 shares of the biopharmaceutical company's stock worth $2,954,000 after purchasing an additional 1,006 shares during the period. Finally, MetLife Investment Management LLC raised its position in shares of Gilead Sciences by 1.9% during the fourth quarter. MetLife Investment Management LLC now owns 329,898 shares of the biopharmaceutical company's stock valued at $30,473,000 after buying an additional 6,109 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 0.5%

NASDAQ GILD opened at $118.37 on Monday. Gilead Sciences, Inc. has a 52 week low of $72.89 and a 52 week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock's 50 day moving average price is $111.88 and its two-hundred day moving average price is $108.50. The stock has a market capitalization of $146.87 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $8,734,625 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on GILD. Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $114.82.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.